a genetic basis
The US Food and Drug Administration (FDA) has approved the world''s first drug that treats cancer on a genetic basis, targeting children and adults. In a statement Thursday, the commission said that the new drug bears the name "Vitrakvi" and mainly targets the genetic mutations of cancerous tumors, regardless of the type of disease or where it originated.
She added that the drug is aimed at treating adult cancer patients and children with solid tumors, or if surgical removal of tumors is likely to lead to serious morbidity, and he has no native treatments, or cases that have not responded to the available treatments.
The drug is presented in two forms: the first in tablets or capsules, and the other in particular, a syrup for children.
To test the safety and efficacy of the drug, FDA approval came after three clinical trials involving 55 pediatric and adult patients with solid tumors, who had no native treatments.
The team monitored a total response rate of 75% across different types of solid carcinomas, and these responses were permanent.
Tumors treated with the drug included soft tissue tumors, a rare type of muscle, fat or fibrous cancer, as well as salivary gland cancer, thyroid cancer, and lung cancer.
"Certification of leave and the introduction of this drug is an important step for cancer treatment, because it treats it at its source," said US Food and Drug Commissioner Scott Gottlieb.
Gottlieb added that the new drug will help cancer patients get the appropriate treatment, and contribute to the treatment of people with different cancerous tumors, but they have common genetic mutations.
Source: Anatolia Agency
